Cargando…

Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018

It is unclear how treatment advances impacted the population‐level survival of patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM). Therefore, we assessed trends in first‐line therapy and relative survival (RS) among patients with LPL/WM diagnosed in the Netherlands betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Amaador, Karima, Kersten, Marie José, Visser, Otto, Brink, Mirian, Posthuma, Eduardus F. M., Minnema, Monique C., Vos, Josephine M. I., Dinmohamed, Avinash G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292034/
https://www.ncbi.nlm.nih.gov/pubmed/34605017
http://dx.doi.org/10.1111/bjh.17856
_version_ 1784749273784516608
author Amaador, Karima
Kersten, Marie José
Visser, Otto
Brink, Mirian
Posthuma, Eduardus F. M.
Minnema, Monique C.
Vos, Josephine M. I.
Dinmohamed, Avinash G.
author_facet Amaador, Karima
Kersten, Marie José
Visser, Otto
Brink, Mirian
Posthuma, Eduardus F. M.
Minnema, Monique C.
Vos, Josephine M. I.
Dinmohamed, Avinash G.
author_sort Amaador, Karima
collection PubMed
description It is unclear how treatment advances impacted the population‐level survival of patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM). Therefore, we assessed trends in first‐line therapy and relative survival (RS) among patients with LPL/WM diagnosed in the Netherlands between 1989 and 2018 (N = 6232; median age, 70 years; 61% males) using data from the nationwide Netherlands Cancer Registry. Patients were grouped into three age groups (<65, 66–75 and >75 years) and four calendar periods. Overall, treatment with anti‐neoplastic agents within 1 year post‐diagnosis gradually decreased over time, following a broader application of an initial watch‐and‐wait approach. Approximately 40% of patients received anti‐neoplastic therapy during 2011–2018. Furthermore, use of chemotherapy alone decreased over time, following an increased application of chemoimmunotherapy. Detailed data among 1596 patients diagnosed during 2014–2018 revealed that dexamethasone‐rituximab‐cyclophosphamide was the most frequently applied regimen; its use increased from 14% to 39% between 2014 and 2018. The 5‐year RS increased significantly over time, particularly since the introduction of rituximab in the early–mid 2000s. The 5‐year RS during 1989–1995 was 75%, 65%, and 46% across the age groups compared to 93%, 85%, and 79% during 2011–2018. However, the survival improvement was less pronounced after 2011. Collectively, the impressive survival improvement may be accounted for by broader application of rituximab‐containing therapy. The lack of survival improvement in the post‐rituximab era warrants studies across multiple lines of therapy to further improve survival in LPL/WM.
format Online
Article
Text
id pubmed-9292034
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92920342022-07-20 Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018 Amaador, Karima Kersten, Marie José Visser, Otto Brink, Mirian Posthuma, Eduardus F. M. Minnema, Monique C. Vos, Josephine M. I. Dinmohamed, Avinash G. Br J Haematol Haematological malignancy–Clinical It is unclear how treatment advances impacted the population‐level survival of patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM). Therefore, we assessed trends in first‐line therapy and relative survival (RS) among patients with LPL/WM diagnosed in the Netherlands between 1989 and 2018 (N = 6232; median age, 70 years; 61% males) using data from the nationwide Netherlands Cancer Registry. Patients were grouped into three age groups (<65, 66–75 and >75 years) and four calendar periods. Overall, treatment with anti‐neoplastic agents within 1 year post‐diagnosis gradually decreased over time, following a broader application of an initial watch‐and‐wait approach. Approximately 40% of patients received anti‐neoplastic therapy during 2011–2018. Furthermore, use of chemotherapy alone decreased over time, following an increased application of chemoimmunotherapy. Detailed data among 1596 patients diagnosed during 2014–2018 revealed that dexamethasone‐rituximab‐cyclophosphamide was the most frequently applied regimen; its use increased from 14% to 39% between 2014 and 2018. The 5‐year RS increased significantly over time, particularly since the introduction of rituximab in the early–mid 2000s. The 5‐year RS during 1989–1995 was 75%, 65%, and 46% across the age groups compared to 93%, 85%, and 79% during 2011–2018. However, the survival improvement was less pronounced after 2011. Collectively, the impressive survival improvement may be accounted for by broader application of rituximab‐containing therapy. The lack of survival improvement in the post‐rituximab era warrants studies across multiple lines of therapy to further improve survival in LPL/WM. John Wiley and Sons Inc. 2021-10-03 2022-02 /pmc/articles/PMC9292034/ /pubmed/34605017 http://dx.doi.org/10.1111/bjh.17856 Text en © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Haematological malignancy–Clinical
Amaador, Karima
Kersten, Marie José
Visser, Otto
Brink, Mirian
Posthuma, Eduardus F. M.
Minnema, Monique C.
Vos, Josephine M. I.
Dinmohamed, Avinash G.
Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018
title Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018
title_full Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018
title_fullStr Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018
title_full_unstemmed Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018
title_short Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018
title_sort primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/waldenström macroglobulinaemia: a population‐based study in the netherlands, 1989–2018
topic Haematological malignancy–Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292034/
https://www.ncbi.nlm.nih.gov/pubmed/34605017
http://dx.doi.org/10.1111/bjh.17856
work_keys_str_mv AT amaadorkarima primarytherapyandrelativesurvivalinpatientswithlymphoplasmacyticlymphomawaldenstrommacroglobulinaemiaapopulationbasedstudyinthenetherlands19892018
AT kerstenmariejose primarytherapyandrelativesurvivalinpatientswithlymphoplasmacyticlymphomawaldenstrommacroglobulinaemiaapopulationbasedstudyinthenetherlands19892018
AT visserotto primarytherapyandrelativesurvivalinpatientswithlymphoplasmacyticlymphomawaldenstrommacroglobulinaemiaapopulationbasedstudyinthenetherlands19892018
AT brinkmirian primarytherapyandrelativesurvivalinpatientswithlymphoplasmacyticlymphomawaldenstrommacroglobulinaemiaapopulationbasedstudyinthenetherlands19892018
AT posthumaeduardusfm primarytherapyandrelativesurvivalinpatientswithlymphoplasmacyticlymphomawaldenstrommacroglobulinaemiaapopulationbasedstudyinthenetherlands19892018
AT minnemamoniquec primarytherapyandrelativesurvivalinpatientswithlymphoplasmacyticlymphomawaldenstrommacroglobulinaemiaapopulationbasedstudyinthenetherlands19892018
AT vosjosephinemi primarytherapyandrelativesurvivalinpatientswithlymphoplasmacyticlymphomawaldenstrommacroglobulinaemiaapopulationbasedstudyinthenetherlands19892018
AT dinmohamedavinashg primarytherapyandrelativesurvivalinpatientswithlymphoplasmacyticlymphomawaldenstrommacroglobulinaemiaapopulationbasedstudyinthenetherlands19892018